In a mouse B16-SIY melanoma model, the NDP-MSH-anti-PD-L1 bispecific antibody showed enhanced antitumor efficacy compared with the parental antibody at 5 mg/kg.
In plain wordsIn mice with melanoma, an antibody carrying NDP-MSH worked better against tumors than the parent antibody alone.
- Peptide
- Melanotan I (afamelanotide)
- Outcome
- IncreaseAntitumor efficacy versus parental antibody
- Study
mousen: not reported in source
Syngeneic B16-SIY melanoma mouse model- Comparator
- Parental antibody (avelumab)
- Outcome group
- Tumor growth · Cancer
Source sentences
This bispecific antibody can bind to both the melanocortin-1 receptor (MC1R) and to PD-L1 expressed on melanoma cells and shows enhanced specific antitumor efficacy in a syngeneic B16-SIY melanoma mouse model compared with the parental antibody at a 5 mg/kg dose.
1 context sentence(design, population, supporting numbers)
To direct checkpoint inhibition to the tumor microenvironment, while avoiding systemic immune activation, we have synthesized a bispecific antibody [norleucine4, d-Phe7]-melanocyte stimulating hormone (NDP-MSH)-antiprogrammed cell death-ligand 1 antibody (αPD-L1) by conjugating a melanocyte stimulat…
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).